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Antje Bischof1* and Till Sprenger1,2Abstract
We report the case of a 49-year-old woman with painful trigeminal neuropathy in the right maxillary division
attributed to a multiple sclerosis plaque as the presenting symptom of multiple sclerosis. The patient was initially
treated with intravenous corticosteroids and was pain free on pregabalin for six months. She was then started on
an immunomodulatory treatment and coinciding with the up-titration of interferon beta-1a, she experienced
recurrence of painful trigeminal neuropathy as well as weekly migraine attacks. Worsening of primary headache
disorders by interferon treatment has been previously reported. Our case suggests that treatment with interferon
beta may also exacerbate symptomatic trigeminal neuralgia in multiple sclerosis.
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Cranial neuralgias, most notably trigeminal neuralgia,
are common symptoms in multiple sclerosis (MS) [1].
In contrast to classical trigeminal neuralgia, which is
thought to be caused by neurovascular compression at the
root entry zone of the trigeminal nerve, symptomatic
trigeminal neuralgia (“painful trigeminal neuropathy
attributed to an MS plaque” according to ICHD-3 beta
nomenclature [2]) in MS typically relates to demyelinating
brainstem lesions at the trigeminal entry level or the tri-
geminal nucleus. Worsening of primary headache disorders
by interferon treatment in MS patients has been previously
reported [3]. Here we describe a case suggesting that treat-
ment with interferon beta may also exacerbate symptomatic
trigeminal neuralgia in MS.Case presentation
We report on a 49-year-old caucasian woman presenting
with excruciating paroxysmal electrical pain within the
right maxillary division of the trigeminal nerve. The pa-
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reproduction in any medium, provided the origPain occurred in a stereotyped fashion and episodes with
repetitive short lasting pains lasted for up to 15 minutes
without persistent pain between the paroxysms. It was trig-
gered by touching the face or eating. No cranial autonomic
symptoms were seen. She had a previous history of mi-
graine without aura with infrequent attacks for years and
a past medical history of hypercholesterolemia and lumbar
discectomy. The family history was negative for headache.
One sister had died from multi-organ failure probably due
to long standing alcoholism.
The neurological exam revealed hypoesthesia to touch
and pinprick hypoalgesia in the maxillary division of the
trigeminal nerve on the right side without mechanical
or thermal hyperalgesia. In addition, saccadic eye move-
ments, incomplete internuclear ophthalmoplegia, loss of
vibration in the distal lower extremities and brisk tendon
reflexes were observed.
Cranial and spinal MRI showed multiple periventricu-
lar, subcortical and juxtacortical T2-hyperintense lesions
as well as infratentorial and spinal lesions. None of the
lesions was contrast enhancing. Of note, one lesion was
located in the area of the right trigeminal nucleus caudalis
within the medulla oblongata (see Figure 1). There were
no signs of neurovascular compression within the right
trigeminal nerve root entry zone. Lumbar puncture showed
five oligoclonal bands and an elevated IgG-Index withr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 Sagittal 3D FLAIR MR image acquired at 1.5 Tesla
(Siemens Avanto) showing a hyperintense lesion in the medulla
oblongata (arrow). FLAIR = fluid attenuated inversion recovery.
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abnormal on the left.
Retrospectively, the patient reported an acute sensory
loss for touch and pain one year before in the left hand
and foot, which had persisted. A diagnosis of MS ac-
cording to the revised McDonald criteria 2010 was
made after an extensive work-up showed no evidence
of alternative diagnoses [4].
After treatment with intravenous corticosteroids with
oral tapering for 14 days and pregabalin 200 mg/d, the
trigeminal pain improved significantly. With cessation of
corticosteroids, symptoms worsened again, but with prega-
balin dose increase from 200 mg/d to 500 mg/d she became
pain free. Pregabalin was later slowly reduced to 250 mg/d
to reduce side effects without reoccurrence of attacks
for 4 months. The patient was then started on an immuno-
modulatory treatment for MS. She decided to start intra-
muscular interferon beta-1a. To minimise side effects, a
four-week titration scheme was used (weekly quarter-dose
increments over four weeks to full dose [30 μg]). When
reaching three-quarters of the target dose, she started
experiencing flu-like symptoms and occasional migraine
attacks the day after the injection. At the same time, she
noted a recurrence of painful trigeminal neuropathy with
two attacks occurring after the injection. At full target
dose, intensity and frequency of symptomatic trigeminal
neuralgia strongly increased and she now always experi-
enced migraine attacks the day after the interferon injec-
tions, whereas no migraine attacks occurred on any other
days throughout the month. At this point, she was unable
to brush her teeth or touch the skin without immediately
evoking neuralgic pains. The pregabalin dose was aug-
mented to 500 mg/d and combined with metamizole.
After the pregabalin dose increase, the pain improvedand metamizole was tapered. Seven months later, she
continues to have flu-like symptoms and migraine attacks
after each injection requiring high doses of non-steroidal
anti-inflammatory drugs, but does not have attacks of
trigeminal neuralgia while on pregabalin. Because of the
temporal relationship between interferon treatment and
recurrence of trigeminal neuralgia and regular migraine
attacks, we discussed the possibility of switching the im-
munomodulatory treatment to glatiramer acetate with the
patient. However, she preferred continuing the treat-
ment with interferon, because of injection-related anxiety
(injection frequency is higher with glatiramer acetate).
Conclusions
This is to our knowledge the first detailed report of a case
with an exacerbation of symptomatic trigeminal neuralgia
in parallel to the onset of an immunomodulatory treat-
ment for MS. Painful trigeminal neuropathy attributed to
a multiple sclerosis plaque is defined by ICHD-3 beta cri-
teria as pain clinically similar to classical trigeminal neur-
algia [2]. Pain can be evoked by triggering stimuli such as
touching or chewing. In symptomatic trigeminal neuralgia
(ICHD-2), there may be sensory impairment in the corre-
sponding division. Our patient fulfilled ICHD-2 criteria
for symptomatic trigeminal neuralgia [5] and ICHD-3
criteria for painful trigeminal neuropathy attributed to a
multiple sclerosis plaque [2]. The exact pathophysiological
mechanisms of symptomatic trigeminal neuralgia remain
unclear. In MS, demyelination of the myelinated part of the
trigeminal root entry zone is a possible cause of neuralgia
by ephaptic excitation of juxtaposed axons [6]. Cruccu et al.
found a high lesion probability in the intrapontine trigemi-
nal primary afferents in MS patients with symptomatic tri-
geminal neuralgia compared to controls and patients with
trigeminal sensory disturbances [1]. Interestingly, there was
no pontine lesion in our patient, but a lesion in the medul-
lary trigeminal nucleus caudalis (Figure 1), which may have
caused the trigeminal pain.
Regarding the possible effects of interferon treatment
on trigeminal neuralgia in MS patients, there is only one
case mentioned in the literature. This patient participated
in the OWIMS study (pivotal interferon beta-1a-study)
in the lower dose group and trigeminal neuralgia was
reported to occur as serious adverse event, but no de-
tails of this case were published [7]. Dose dependent
aggravation of primary headache, notably migraine, by
interferon treatment has been repetitively described in
MS patients [3]. Exact mechanisms how interferon
treatment may affect headache and pain disorders are
unclear. Nakatsuji et al. described an increase of inter-
leukin 6 and TNF-alpha levels following interferon beta
administration, which was associated with the develop-
ment of post-injection headache and arthralgia [8]. Effects
of interferon beta on cytokine levels may hence explain
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nal neuralgia in our patient.
In patients with primary headache, a comparison between
interferon and glatiramer acetate treatment showed that in
contrast to interferons, glatiramer acetate did not aggravate
pre-existing or evoke new-onset headache [9]. To us it
seems logical that the results of this study might be applic-
able to patients with trigeminal neuralgia, too, as our pa-
tient had a clear worsening of her symptomatic trigeminal
neuralgia with the beginning of interferon beta-1a therapy,
when her migraine also worsened. Whether newer MS
treatments such as Teriflunomide, Dimethylfumarate
or Fingolimod may impact primary or secondary headache
disorders is not yet clear.
With this report we want to stress the possible clinical
implications of interferon treatment on MS patients with
pain syndromes, whether symptomatic or primary. Pain
syndromes are a common finding in MS patients and the
potential effects of immunomodulatory treatments on such
headache and pain syndromes are often not sufficiently
considered during immunomodulatory treatment evalu-
ation. This is an important clinical consideration as pain
may affect compliance with treatment and hence reduce
the efficacy of the immunomodulation. Alternatives to
interferon treatment should be considered in patients
with symptomatic trigeminal neuralgia if there is new
onset or recurrence of pain during treatment initiation
and the pain difficult to control.Consent
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